Return to Science Search homepage
Return to Project List
|
European bat lyssavirus pathogenesis and immuno-biological assay development - SE0418
|
Description
Information on the effectiveness of current rabies virus (RV, genotype 1) vaccines in cross-protection against the European Bat Lyssaviruses (EBLs, genotypes 5 & 6) is limited and fragmentary. This project aims to study neutralisation, protection, susceptibility and pathogenesis of EBLs in order to understand the level of risk that they pose to the UK.
The main objectives of this proposal are:
To develop modified virus neutralisation (FAVN) tests for EBLs and determine if licensed RV vaccines elicit cross-neutralising antibodies to EBLs.
To determine if RV vaccines confer cross-protection against EBLs. This will include two EBL disease models; mouse studies at VLA and fox studies in collaboration with AFSSA (Nancy, France).
To determine species susceptibility to EBLs in vitro.
To study EBL disease pathogenesis using novel cell and animal models.
This research will fulfil DEFRA ROAME A objectives to minimise the risk of transmission of zoonotic infections, disease diagnosis, control and surveillance and will improve our understanding of EBL disease pathogenesis.
|
Objective
To develop modified virus neutralisation (FAVN) tests for EBLs and determine if licensed RV vaccines elicit cross-neutralising antibodies to EBLs.
To determine if RV vaccines confer cross-protection against EBLs. This will include two EBL disease models; mouse studies at VLA and fox studies in collaboration with AFSSA (Nancy, France).
To determine species susceptibility to EBLs in vitro.
To study EBL disease pathogenesis using novel cell and animal models. |
Project Documents
• Final Report : European Bat Lyssavirus pathogenesis and immuno-biological assay development
(476k)
|
Time-Scale and Cost
From:
2002
|
To:
2006
|
|
Cost: £675,386 |
|
Contractor / Funded Organisations
Veterinary Laboratories Agency |
Keywords
|
Fields of Study
Animal Health |